MYDA Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

MYDA Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-21,200	Closed	-$51.9K	–	205
2025 Q2	$51.9K	Sell	21,200 -61,000	-74%	-$309K	0.01%	140
2025 Q1	$548K	Buy	+82,200	New	+$812K	0.1%	115

Other funds holding RCKT

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

MYDA Advisors's RCKT Position: Q4 2025 in Review

MYDA Advisors sold out of Rocket Pharmaceuticals (RCKT) in Q4 2025, closing a stake of 100,000 shares — an estimated $326K sold.

MYDA Advisors first reported a position in RCKT in Q1 2025 and held it in 3 quarters. The position peaked at $3.07M in Q1 2025. 186 funds tracked by Wall St. Rank hold RCKT as of Q4 2025.

MYDA Advisors reported no remaining Rocket Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
MYDA Advisors sold 100,000 Rocket Pharmaceuticals shares in Q4 2025, an estimated $326K.
MYDA Advisors first reported a position in Rocket Pharmaceuticals in Q1 2025 and held it in 3 quarters.
MYDA Advisors's Rocket Pharmaceuticals position peaked at $3.07M in Q1 2025.
186 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2025.

Based on MYDA Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.